Hospital

This reduction in white matter has been well-documented, but the exact mechanism of action has been unknown until now, according to the study authors.

Evinacumab-dgnb is the first FDA-approved treatment that binds to and blocks the function of angiopoietin-like 3, a protein that plays a key role in lipid metabolism.

Working in clinical research combines skills from both the retail and health system pharmacy spaces, as well as other, more unique skillsets, according to research pharmacist Brian Wortz, PharmD, of Cancer Treatment Centers of America, in an interview with Pharmacy Times.

Individuals receiving aducanumab showed significant dose- and time-dependent reduction of amyloid beta plaque, whereas patients in the control arm had no reduction, according to the FDA.

Research pharmacist Brian Wortz, PharmD, with Cancer Treatment Centers of America, said working as a pharmacist in clinical research provides interesting opportunities to be at the forefront of drug development.

Study highlights the importance of developing solid relationships with patients, so they are comfortable asking questions and trust pharmacists with their care.

If it were to be approved now, the drug would be used in patients with metastatic castration-resistant prostate cancer who have progressed on an androgen receptor-directed therapy and 1 to 2 taxane-based chemotherapeutics.

The investigative therapy targets a specific molecule that is generally only expressed on the prostate cancer cell, according to a recent interview.

Medical oncologist Michael Morris, MD, discussed the newest findings of the phase 3 VISION trial, which is investigating the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.

Notably, the investigative treatment avoids many of the severe adverse effects common in traditional therapies.

Bemarituzumab is an investigational, potential first-in-class targeted antibody designed to block specific fibroblast growth factors from binding and activating FGFR2b.

Research has also shown activity with sacituzumab govitecan in subsets of patients with triple-negative breast cancer, such as those with active brain metastases.

The use of 177Lu-PSMA-617 resulted in a 60% reduction in radiographic progression or death among patients with advanced prostate cancer.

In PD-L1-positive patients, tislelizumab improved median overall survival by 3.5 months with a 46% decrease in the risk of death compared with chemotherapy.

New research presented at the American Society of Clinical Oncology 2021 annual meeting has found encouraging results with the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.

Study suggests that 8 out of 10 patients with breast cancer who receive treatment with TARGIT-IORT will not need a long course of post-operative external beam radiotherapy.

Understanding how formularies work is essential in the world of pharmacy and knowledge on this topic can help pharmacists to better serve patients.

The researchers found that the proportion of patients requiring in-patient endoscopic interventions for their alcohol-related gastrointestinal and liver conditions increased.

Pharmacy Times spoke with Tomas Villanueva, DO, MBA, FACPE, SFHM, practicing health care provider, and associate vice president for clinical resources at Vizient, about what pharmacists should know about vaccine hesitancy in general.

Catherine Duggan, FRPharmS, CEO of International Pharmaceutical Federation, discusses the role and the authorities of the pharmacist internationally, and the effect the pandemic has had on that role globally.

Frequent prostate-specific antigen screenings may lower the risk of metastasis at the time of diagnosis and lower mortality risk from prostate cancer among younger African American men.

Although many health systems offer wellness program for their staff, awareness and utilization of these services remains low.

Rates of death among patients with breast cancer due to any cause were 31% higher in states with Medicaid income eligibility limits no greater than 50% of the federal poverty level.

According to the study authors, 9% of the children receiving the combination therapy did not respond to treatment, compared to 51% of children receiving IVIG alone.

This is the first and only oncology immunotherapy to show positive phase 3 results in the adjuvant lung cancer setting.

As pharmacy professionals battle with their own challenges regarding mental health, the optimal role of psychiatric pharmacists is yet to be defined.

Both health care providers and the general public said skin dryness is a major obstacle for consistent hand hygiene practices.

Pharmacy Times spoke with Tomas Villanueva, DO, MBA, FACPE, SFHM, practicing health care provider, and associate vice president for clinical resources at Vizient, about the value of the pharmacist in addressing vaccine hesitancy.

Pharmacy Times spoke with Tomas Villanueva, DO, MBA, FACPE, SFHM, practicing health care provider, and associate vice president for clinical resources at Vizient, about how hospitals are tailoring their approaches to vaccine hesitancy to address social detriments.

The investigational therapy RBX2660 has demonstrated positive trends in efficacy and safety for reducing recurrent Clostridioides difficile (C. difficile) infection over 6 months, in a recent study.